Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Eutroxsig
Active Ingredient: Levothyroxine sodium, anhydrous 100µg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Australia Pty Limited, Dandenong, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Product: Eutroxsig
Active Ingredient: Levothyroxine sodium, anhydrous 200µg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Australia Pty Limited, Dandenong, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Product: Eutroxsig
Active Ingredient: Levothyroxine sodium, anhydrous 50µg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Australia Pty Limited, Dandenong, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Product: Eutroxsig
Active Ingredient: Levothyroxine sodium, anhydrous 75µg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Australia Pty Limited, Dandenong, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 30th day of January 2009.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).